Better that than a p*** up at the pub where DEMG shareholders can go to a wake and drown their sorrows. Only question is who buys the rounds? The investor s who are broke or the DEMG management who are expert at p**ing money away up the wall?
You could be right, but surely the CardioQ is supposed to save money, although I appreciate it may be down to the timing regarding end of financial year, another reason why we shareholders deserve to know the reasons why none renewal.
As to no 10 buses, it may be that I should have put my money into a bus company. Would be nice to see 3 contracts come along all at once and be substantial.
US hospital accounts are I fear a bit like No 24 buses. London buses make up 10% of passing vehicles but even on Victoria Street you can wait half an hour for an every 4-5 min service and then 3 come along one behind the other. But I wonder if this is the barter pre-payment release? Picked up an early account on very favourable terms that they could not afford to renew and the hospital dropped the account?
Trading pattern today is interesting too, 4m traded by lunch would usually be associated with a price move but since 1000 someone has been mopping up any sales at or around the mid-price. I watch with interest, and continue to hold an interest.
I do not think the share price will be soaring today but I continue to hold. Invoice discounting has largely disappeared, we now have pre-payment bartering. Is that a reflection of the shift to USA? You ask:
"does anyone think that by year end, or even by the first quarter of 2019, the company will finally be in profit." My view is yes but there is the dog that did not bark - Last year the first half was good and second disappointing. We have had 4 out of 6 months of year to 2018. There is no mention in forward looking statements. That is not a good sign. It might become clearer in the formal annual report.
Although throughout the year we have seen increased contracts, mainly in the USA the company is still not in profit, although we were told that profit was near a couple of years ago.
Operating loss is still evident but reduced by £0.4m to £2.0m (2016: £2.4m), so loss only reduced by 20%.
Group revenues £0.4m lower at £5.9m (2016: £6.3m) one has to wonder why, if they have more units and probes being used.
Even with gross margins improved to 75% (2016: 68%) the company is still loosing money.
With statements such as 'Revenues from US managed care contracts down 20% at £0.4m (2016: £0.5m) due to one lost account' '2017 was partially offset by a disappointing second half sales performance'. You have to wonder why they are loosing accounts if the system is as good and cost effective as the company states (I do believe it is as good as we have been told, so there's the mystery.
I have never seen a product that has so many positive trials and feedback fail so miserably to almost by results contradict the figures from those trials.
As many of us have stated, It can only be down to the companies business model.
Can anyone can give a better explanation. Also does anyone think that by year end, or even by the first quarter of 2019, the company will finally be in profit.
With the separate release re the TrueVueTM System, (which I read first finishing with a positive feeling that was reversed on reading the results) I still feel the SP will either open down, or if upward will as ever drift ever downward again.
They were only looking for £500k, they probably found most of that down the back of the fund manager's sofa. But as you point out it is interesting that there is no RNS showing a significant holding but if fund holders took up a proportion in relation to their shareholding there would be no levels crossed and no need for RNS. In the last annual accounts there is no table of major holders. The last RNS for major holder were mid 2017 Herald and Hambro.
Hi hangover, you are correct IMO - if the proposition is a good as some have long suggested then the technology would have been bought out. Researching over the recent statements I think the reality is - the product is good but it requires skill to use it and is only practical in asleep patients because of the gag reaction. This means the technology is difficult to introduce across a hospital, from nurse to surgeon and between asleep/awake patients. They are trying to ameliorate this hurdle by combining ODM with easier to use technologies like ppwa - particularly for monitoring - while at the same time pushing for greater adoption of ODM by surgeons as an intervention tool. Hopefully over time, the techniques are better understood and can spread down the chain. Ewan has just purchased a substantial number of shares, the first time he has done so as far back as I can remember - which suggests that those really in the know believe things may be on the up. Fingers crossed
I held this share years ago and got out at a loss.
As stated research such as this should be compelling and over the years it has come from many institutions in many countries.
The management may be awful at getting the product into hospitals - have the wrong strategy etc. but why if the product is good does Deltex not become a takeover target? Is that not capitalisms supposed route of removing poor management teams - I assume most shareholders offered a reasonable price may sell?
I am very close to buying again some 5 or so years after I sold out on the basis that I see lots of new starts with ridiculous valuations and this surely has value buried within it and my past experience IQE being one is sometimes you can give up too early....if I owned I'd definitely hold and I'm tempted to join those that do!
I appreciate he bought in the fund raising, but it would have looked very bad if he had not done so.
My post a few minutes earlier this morning probably goes some way to explaining why perhaps my frustration with this share often does get the better of me.
One of the reasons I get very frustrated and even angry at the Deltex management is that with results like these the product should be flying off the shelves and the sp should be soaring.
There is no getting away from the fact as myself and others have said many times, the product is a no brainer and with these results and similar prior results one has to continually look for reasons why it is not a medical product of the first order.
Most companies after a RNS such as this, would see their sp flying upward and more importantly staying there. But will be see this with Deltex, if so it will be a nice and unexpected change of direction.
Deltex Medical's Oesophageal Doppler Monitoring System, reduces postoperative complications by 75 per cent.
75 per cent. fewer complications, significant reductions of between 75 per cent. and 100 per cent. in several specific major complications including acute kidney injury, acute pulmonary oedema, respiratory distress syndrome, pneumonia, and both superficial and deep surgical site infection.
The number of patients suffering at least one post-operative complication was halved and median length of stay for patients in the GDHT group was two days shorter than the control group.
Pond - You should do some research before posting. Ewan purchased 1.6m shares in the cash raise at 1.25p and 800k shares at 1p using options. Furthermore, he wanted to purchase more in the raise but was scaled back. In total, he spent nearly £30k.
Yes he bought 800,000 at an exercised price of 1.00p so a massive buy (not) of £8,000 when the market price was 1.28p.
It is when I see him buying on the open market that I will start to take notice but there again why should he when he has been granted so many shares on option.
He is in a win win position.
It is interesting to note, I think, that for the first time I can remember Ewan Phillips has bought shares in Deltex. Looking at the price chart he has been right to abstain, so I wonder if this is a tipping point. For all the optimism and disappointment, and discussion about what is going on with the underlying business, I suspect he is one of very few who has a clear idea of what is going on. Heres to hoping
Meant to add, As the extended tender in 2014 does not say for how long, we do not know if it was till 2018, IE the date of the latest. Do you know if the tender was extended in 2014 for 4 years, because I don't. It probably was, but if so it is another example of a lacking detail news issue from Deltex.
Even when you are right your sarcasm does nothing to enhance your arguments. I have no problem with persons posting opposing views, but why get peoples backs up just because they disagree with you.
I have been in Deltex since they first floated on the markets, although only a token gesture now held and so have had my faith in the company knocked so many times that I no doubt find it harder to believe that those who are quite new to the company.
When I see yet another RNS followed by a uptick quickly followed by the usual drop down I find it more and more difficult to stay positive.
To return to DEMG. France was an early "export" market and very much monitor, cash up front, and cheap(er) probes. I think the US model is the way forward (cheap/loan of) monitor and more costly probes. That would be counter-intuitive to an accountant but the NHS has two budgets, capital and consumables. As a retired clinician the name of the game was to refuse all capital spending by the department until March and unless I got my bid in within 24 hrs the department budget capital was spent on new iPhones for the managers. I did a couple of years as a GP in France (Val d'Isere) but I think the same might apply.
They have an agent in France, looks like agent will supply about a third of monitors.... "from stock" but essentially head office loan the monitors, local agent still gets the cut on the probes, but they now cost about 1/4 of manufacturing cost in 2011.
Just my take.
Seadoc (headed off to 35Deg S on Tuesday, enjoy the Siberian blast next week)
Guilty as charged about my poorly informed posts that were the first to describe DEMG as a serial issuer of news shares that fell below issue price on each occasion and that decried DEMG's plaintive RNSs reporting new customers that seemingly fail each time to afford a better financial performance.
Your analysis of what happens after news omits the phase when RAConnell and pond1 make negative or poorly informed posts about the news and then Fokisi, who has probably never owned any shares, comes trip trap trapp trapping along and asks crafty questions to which the answers could only be negative. Eventually seadoc turns up and says something more sensible but normally from somewhere foreign and exotic which only makes the rest of us all sad and jealous
The RNS said: "replaces a previous tender originally awarded in 2011 and extended in 2014"
You said: "A new tender that replaces the one between 2011 and 2014, anyone have any idea why there is a gap of 4 years"
Might it be that the tender originally awarded in 2011 was extended in 2014? Just a thought, could be wrong, DYOR etc etc
As you say not a bad profit from 1.04p and good luck to any profit makers of this company.
One of the repeating problem of this companies sp, is that news is released, sp goes up, current investors outnumber any looking to invest, they take what profit they can knowing that within a couple of days the sp will return to it's former pre news price. It's almost the forgone conclusion of the roundabout, it always returns to the same spot.
The only thing that will sustain a risen sp is several decent, profit showing contracts one after the other.
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.